Vicor Technologies, Inc. (OTCBB: VCRT)  Vicor Profile Stock Guru

This is a bio-tech company that HAS GOT IT ALL.

I understand that these words sound like an overstatement but when you look at the Publications, the Field Trials and the Presentations associated with Vicor you realize — this is NOT an overstatement:

Vicor Technologies is Delivering

A NEW VITAL SIGN

With the Ability to Save Lives in Combat and Civilian Settings

As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%.

No stress-testing or any active participation from the patient is required.

A large physician shareholder base represents the early adoptees of this Company.

The PD2i™ Nonlinear Algorithm has been cleared by the FDA for marketing as a measure of Heart Rate Variability and already has a billing code — so providers can be paid.

Vicor’s PD2i™ Nonlinear Algorithm

The PD2i Analyzer™ can capture and display Heart Rate Variabilityin patients at rest and during paced respiration and controlled exercise.

• Able to identify trauma victims in need of an immediate lifesaving intervention
• Able to be used along with other clinical data to identify patients at risk of sudden cardiac death
• Able to be used along with other clinical data to identify patients who have autonomic dysfunction
• Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed
• Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting
• Not derailed in delivering actionable results by noisy raw EKG data
• Functional in trauma environments and battlefield situations

Vicor’s Three Products Employing the PD2i™ Nonlinear Algorithm.

• PD2i Analyzer(TM) has FDA 510(k) marketing clearance. It measures Heart Rate Variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes.
• PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
• PD2i CA(TM) (Cardiac Analyzer) identifies patients at risk of sudden cardiac death and is in multiple clinical trials.

This image is important because it demonstrates how EASY it is to use the PD2i Analyzer™.  This truly is A NEW VITAL SIGN.

The PD2i Analyzer™ has been cleared by the FDA for marketing as a measure of Heart Rate Variability. It quantifies the relationship between the patient’s heart and brain by measuring the heart rate variation over time. The PD2i® test is painless and much like a value-added electrocardiogram. Adhesive sensor pads are placed on the skin and for the next twenty minutes the Analyzer records heartbeat information. Exercise is not necessary during the test.

The PD2i Analyzer™ twenty-minute test is composed of recording a sequence of one thousand heartbeats. The PD2i™ nonlinear algorithm is subsequently applied to that recording in order to find subtle patterns in the resulting data, yielding the final result which is expressed as a minimum PD2i™ value.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.

Yesterday, after a strong down trade based on a wrong perception, Medizone International’s Chairman addressed the issue.

This presents a great opportunity to acquire this stock at a discounted price.

In paraphrasing the Chairman’s Message I have deduced these crucial facts:

• Hospital beta testing is expected to begin by late spring at sites in both the US and Canada
• The first peer reviewed journal article will published which is expected to be this summer
• Commercialization will begin shortly thereafter

There are no fundamental problems here.  Basically, the unexpected success of the kill rate necessitated the need to modify the equipment.

The most important facts taken from Yesterday’s Chairman’s Message are:

It has been brought to my attention by shareholders there has recently been some misunderstanding as to development path time frames for AsepticSure™. This message is intended to hopefully clear up those perceived misunderstandings.

Hospital beta testing is expected to begin by late spring at sites in both the US and Canada.  At this time it is indicated that the first peer reviewed journal article will published which is expected to be this summer.

As you will recall on January 5, 2010, MZEI announced “Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.”

Those first 6-log results achieved in their laboratory unit greatly enhanced the efficacy or the AsepticSure™ product.  This enhanced technology has not yet been integrated into their full-scale equipment.

The development stage machinery required additional engineering prior to being ready for hospital beta testing and production.

Currently, utilizing the expanded and enhanced design team that is experienced in bringing products from the research stage to full production, Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing.

This design is intended to deliver a product into the hospital beta test environment that maintenance staff within the hospital can easily be taught to use with equipment that is 100% reliable.

Medizone noted the expectation that sales should flow smoothly out of a successful beta test program.

Medizone has achieved results in both laboratory and room scale trials that are absolutely unheard of in the scientific and medical communities. The same success in commercialization is expected.

I reiterate my belief that MZEI should be a core holding and it this is a great price.

DALLAS, TEXAS : StockGuru announces that Left Behind Games Inc. (OTCBB: LFBG) is in the StockGuru Spotlight.   Left Behind Games Inc. has become one of the world’s leading independent developers and publishers of quality interactive entertainment products that perpetuate positive values and appeal to mainstream and faith-based audiences.

On Thursday, the company put out news announcing that Berean Christian Stores have approved the sale of Left Behind Games throughout their 18-store chain. In a trial marketing program during the fourth quarter of 2009, up to 30 games per week and $2,500 in sales monthly were sold at just one Berean Christian Store. This was accomplished in conjunction with four “Family Video Game Night” Events at Chick-fil-A restaurants in California. 

Shares for Left Behind Games Inc. (OTCBB: LFBG) were down during the late afternoon of trading on Thursday and closed slightly down at closing.
 

To view our StockGuru Spotlight on Left Behind Games Inc. (OTCBB: LFBG), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that Idaho Independent Bank (OTCBB: IIBK) is in the StockGuru Spotlight.   Idaho Independent Bank was established in 1993 as an Idaho state-chartered, commercial bank and currently operates branches in Boise (3), Meridian, Coeur d’Alene, Nampa, Mountain Home, Hayden, Caldwell, Star, Eagle, and Sun Valley/Ketchum, Idaho.  IIB has approximately 200 employees throughout the state of Idaho.

On Thursday, the company put out news announcing the consolidated unaudited financial results for the fourth quarter and year ended December 31, 2009.  Mr. Gustavel reported that IIB’s net loss for the quarter ended December 31, 2009, was $1.98 million, or a loss of $0.31 per diluted share, compared to a net loss of $3.67 million, or a loss of $0.59 per diluted share, for the same period a year ago. An increase in IIB’s provision for loan losses contributed to a net loss of $6.65 million, or a loss of $1.06 per diluted share, for the year ended December 31, 2009, compared to net income of $1.01 million, or $0.16 per diluted share, for the year ended December 31, 2008.

Shares for Idaho Independent Bank (OTCBB: IIBK) were steady during the day of trading on Thursday and closed with no change at closing.

To view our StockGuru Spotlight on Idaho Independent Bank (OTCBB: IIBK), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that ACRO Inc. (OTCBB: ACRI) is in the StockGuru Spotlight.   Acro, Inc. develops explosives detection technologies and manufactures relevant products. In addition to the explosives detectors that are currently marketed by Acro, the company continues to develop proprietary technologies for the HLS market. Acro’s Advisory Board includes Nobel Prize laureate Prof. K. Barry Sharpless, and Prof. Richard A. Lerner, President and CEO of The Scripps Research Institute, one of the most influential scientific institutes worldwide.

On Thursday, the company put out news announcing that the company has successfully completed the development of its new product, Acro-ANET, a specific tester and a trace-detector of Ammonium Nitrate. The white crystals of ammonium nitrate are commonly used in agriculture as high-nitrogen fertilizer. Unfortunately, this compound is also being used as an improvised explosive by terrorist organizations worldwide. It is the main component of ammonium nitrate fuel oil (ANFO), an increasingly popular component of improvised explosive devices.

Shares for ACRO Inc. (OTCBB: ACRI) were up during the afternoon of trading on Thursday and closed slightly up at closing.

To view our StockGuru Spotlight on ACRO Inc. (OTCBB: ACRI), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that Camelot Entertainment Group Inc. (OTCBB: CMGR) is in the StockGuru Spotlight.   Camelot Entertainment Group, Inc. is a U.S. publicly traded company with three major divisions: Camelot Film Group, which includes Camelot Distribution Group and DarKnight Pictures, Camelot Studio Group and Camelot Production Services Group. Camelot is building a different kind of motion picture studio infrastructure by redefining the development, financing, production, and distribution process. Camelot is a member of the Independent Film & Television Alliance (IFTA).

On Thursday, the company put out news announcing that Camelot Distribution Group acquired Who is K.K. Downey?, a comedy about two hipsters willing to do anything for fame.  A Kidnapper Films and Brandi-Ann Milbradt production, the film is directed by Pat Kiely and Darren Curtis, produced by Pat Kiely, Darren Curtis, Kieran Crilly, and Brandi-Ann Milbradt, and written by Pat Kiely, Darren Curtis, and Matt Silver.  The film stars Montreal’s Kidnapper Comedy Troupe’s Darren Curtis, Matt Silver, Pat Kiely, Dan Haber, and also includes Kristin Adams (Where the Truth Lies), Paul Spence (It’s All Gone Pete Tong).

Shares for Camelot Entertainment Group Inc. (OTCBB: CMGR) were down during the late afternoon of trading on Thursday and closed slightly down at closing.
 

To view our StockGuru Spotlight on Camelot Entertainment Group Inc. (OTCBB: CMGR), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that ClearLite Holdings Inc (OTCBB: CLRH) is in the StockGuru Spotlight.   Clear-Lite Holdings, Inc. is a leading innovator of cutting-edge, eco-friendly CFLs, lamps, and commercial lighting products. The Company’s current line of CFLs are Energy Star® qualified and designed to meet RoHS standards (Reduction of Hazardous Substances), as well as UL approved in the US and Canada. In addition, ClearLite’s newest offering of a patent-pending technology ArmorLite™ and ArmourBulb™ SAFETY ECO CFL™ helps capture broken glass and mercury, which is becoming a concern for many. ClearLite® has strategic partnerships with major global manufacturers and has established cost-effective sales and logistics channels with offices in Florida, Illinois, California and Canada.

On Thursday, the company put out news announcing that the company will be debuting several new product lines during the International Home & Housewares Show from March 14-16 in Chicago, IL.  While most consumers know that compact fluorescent lamps (CFL’s) offer energy savings of up to 75% and last up to 13 times longer than comparable incandescent bulbs, many are unaware that CFL bulbs can also contain liquid mercury, which poses a potential safety risk to both humans and pets if a bulb is broken in the home.

Shares for ClearLite Holdings Inc (OTCBB: CLRH) were up during the afternoon of trading on Thursday and closed up two cents at closing.

To view our StockGuru Spotlight on ClearLite Holdings Inc (OTCBB: CLRH), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that Pro-Pharmaceuticals Inc. (OTCBB: PRWP) is in the StockGuru Spotlight.   Pro-Pharmaceuticals, is a pioneer in the field of Galectin Therapeutics and is engaged in the discovery, development and commercialization of therapeutic compounds that target Galectin receptors for advanced treatment of cancer and fibrosis. Initially, the product pipeline is focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs. The Company is headquartered in Newton, Mass.

On Thursday, the company put out news announcing that the company has closed a $335,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.1 million.

Shares for Pro-Pharmaceuticals Inc. (OTCBB: PRWP) were up during the late afternoon of trading on Thursday and closed up one cent at closing.
 

To view our StockGuru Spotlight on Pro-Pharmaceuticals Inc. (OTCBB: PRWP), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that MedPro Safety Products Inc (OTCBB: MPSP) is in the StockGuru Spotlight.   MedPro Safety Products, Inc. is a leading developer of safer medication delivery and blood collection systems. The Company licenses, develops and manufactures transformational technologies to be marketed through its global medical device partners. MedPro’s products address multiple product categories within the medical delivery (injection and infusion) and blood collection (blood collection sets and blood tubeholders) markets. We believe these products represent the most passive technologies available on the market as they deploy without conscious activation by the user and require little or no clinician training as compared to competitive products. The total global market opportunity currently addressed by the Company’s portfolio of products is estimated to exceed $6 billion.

On Thursday, the company put out news announcing that the company has entered into a Joint Development Agreement (JDA) with Belgium-based Helvoet Pharma for the technical development and commercialization of MedPro’s pre-filled safety syringe (PFSS). 

Shares for MedPro Safety Products Inc (OTCBB: MPSP) were steady during the day of trading on Thursday and closed with no change at closing.

To view our StockGuru Spotlight on MedPro Safety Products Inc (OTCBB: MPSP), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

Chairman’s Message
Shareholder Update

March 11, 2010

It has been brought to my attention by shareholders there has recently been some misunderstanding as to development path timeframes for AsepticSure™. This message is intended to hopefully clear up those perceived misunderstandings.

The end of 2008 and going into early 2009 the company believed it would finalize product development by the end of 2009 with first deliveries during the first quarter of 2010. That has obviously proven to be an overly optimistic time frame, and I accept responsibility for not being more conservative with our projections at that time. Those projections were based on statements made to me by our development partner that the prototype equipment being planned for full-scale room treatment “would be very close to a production prototype.” This clearly has not proven to be the case.

As projects like this involving revolutionary technology and break through science evolve, they do have a tendency to take on a life of their own. Relative to the development of the room scale prototype, initially our development partner fell behind expectations relative to delivery time. Also, and this is a very big positive, on January 5, 2010 we announced “Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.” Those first 6-log results were achieved in our laboratory unit with technology that had not yet been integrated into our full-scale equipment. This incredible scientific accomplishment was explained in the January 10, 2010 press release relating to greatly enhanced patent protection. “This was made possible”, commented Dr Michael Shannon, Medizone’s Director of Medical Affairs, “through the integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative.”

In sum, the goal posts had moved. Additional technologies that greatly enhanced the AsepticSure™ product now had to be integrated into a design that had not originally been considered for this additional technology that greatly enhanced efficacy. Thus, in reality, what was once intended to be “very close to a production prototype,” had clearly become a development machine that required additional engineering prior to being ready for hospital beta testing and production. During the last half of 2009, I tried to soften expectations relative to commercialization time frames in both how press releases were drafted and also with our SEC Filings. I hope this communication will clear up once and for all any misunderstanding.

Currently, utilizing an expanded and enhanced design team that is experienced in bringing products from the research stage to full production, Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing. This design will achieve the same results as the current beta prototype while also being a major step forward and very close to what we expect the full production prototype will be. Shareholders must comprehend, now that we understand the science and clearly understand what is required for open space sterilization such as in hospital settings, it is absolutely essential to deliver a product into the hospital beta test environment that maintenance staff within the hospital can easily be taught to use and the equipment must be 100% reliable. Anything short of that is a recipe for failure. Medizone Management from top to bottom and all of our development staff, are dedicated to that outcome; deliver a first rate, reliable machine, that hospitals can count on. Nothing less will do.

Since I want to be cautious with time frames given past slippages, hospital beta testing is expected to begin by late spring at sites in both the US and Canada. Production developments from the hospital beta system are not expected to be in the hardware or basic design, but more related to things like state of the art packaging. However, let me caution, as I stated earlier in this communication, these things do have a way of taking on a life of their own.

We believe moving from hospital beta testing to initial production and sales at modest rates should prove to be a smooth, manageable transition. We expect sales should flow smoothly out of a successful beta test program. In closing, I think it is important for shareholders to remember that Medizone has achieved results in both laboratory and room scale trials that are absolutely unheard of in the scientific and medical communities. We expect the same success in commercialization.

We are still a small company with limited resources. I am proud of what we have achieved. It is absolutely essential that we not rush this next phase of product development, as it must be done correctly the first time. I assure you both Dr Shannon, myself and all of our team, are putting our full effort into making sure that is the case.

As we successfully transition into hospital beta testing, when the first peer reviewed journal article is published (expected this summer), as partners are announced and the management team and board are expanded to reflect the skill sets of a rapidly growing commercially viable company, our contribution to science and medicine will be clear to all.

Yours truly,

Edwin G. Marshall
Chairman &
CEO
Medizone International, Inc.

This Chairman’s message contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.